Plate Nº 77 · recorded November 17, 2026

Health & Medicine ResearchReported finding

Proposed obesity definition could raise prevalence by up to 7.4%

A Lancet Commission framework combines BMI, waist measurements and 18 signs of organ dysfunction. A four-country study links clinical obesity to 69% higher death risk.

By Elena Vasquez5 min read979 words

In brief

  1. Proposed in January 2025 and validated in Nature on Nov. 11, 2026.
  2. Clinical obesity was linked to 69% greater all-cause mortality than no obesity.
  3. Estimated obesity prevalence would increase by 3.3% to 7.4%.
  4. 77% to 91% of preclinical cases did not progress within 10 years, depending on cohort.
  5. The framework uses BMI plus at least one waist measure and assesses 18 signs of dysfunction.
More people could count as obese under newly proposed definition — here's what you need to know
Plate Nº 77More people could count as obese under newly proposed definition — here's what you need to know — kumarsu6745_ / pixabay

By Elena Vasquez

A proposed obesity definition would raise estimated obesity prevalence by about 3.3% to 7.4%, according to a validation study published Wednesday, Nov. 11, 2026, in Nature.

The four-country study found that body measurements, medical history and signs of organ dysfunction identified mortality risk more precisely than body mass index alone. The evidence supports, but does not settle, a framework first proposed in January 2025.

Obesity is linked to heart disease, diabetes and early death, but clinicians often struggle to determine who faces the greatest risk. BMI, a common screening tool, cannot capture every relevant difference between patients.

What changed in the proposed definition?

Dr. Francesco Rubino, a professor of bariatric and metabolic surgery at King’s College London, recently chaired a team of 56 experts assembled to redefine obesity. Their Lancet Commission proposal retains BMI but adds body measurements and separates “preclinical” from “clinical” obesity.

Rubino said: “BMI misses a lot of information.”

The study, “Validation of clinical and preclinical obesity across global cohorts,” appeared in Nature volume 659. Its authors say the approach would identify more people accurately and reduce the number of patients misclassified by BMI alone.

The researchers used electronic health records from China, the United Kingdom, the United States and Spain. Their clinical-obesity classification flagged death risk better than BMI and showed no clear BMI-mortality association in these cohorts.

Clinical obesity was associated with a 69% greater risk of death from any cause, or all-cause mortality, compared with no obesity. The finding concerns classification; further work must show whether the labels improve care.

The practical shift is from a single threshold toward a fuller assessment of health risk.

How would obesity be assessed?

At its simplest, obesity is excess body fat. Scans and exams that send weak electrical signals through the body can measure body-fat percentage, but body measurements are more accessible across clinical settings.

BMI divides weight by height squared. It ignores individual differences in lean muscle and bone density, and the same “overweight” or “obese” category can carry different risks. Certain racial and ethnic groups tend to experience higher mortality at different BMI levels.

For an individual assessment, the proposed guidelines would use BMI plus at least one additional body measurement and ask the doctor to review medical history for signs of bodily or organ dysfunction. These measurements are less influenced by muscle mass and bone structure than BMI.

  • Waist circumference, the distance around the abdomen.
  • Waist-to-hip ratio, which compares waist size with hip circumference.
  • Waist-to-height ratio, which compares waist size with height.

Ethnicity-specific waist circumference cutoffs would be used because fat distribution patterns differ among ethnic groups. The framework also examines 18 conditions and signs related to obesity, such as cardiovascular disease, joint pain and sleep apnea.

BMI would remain part of screening, but it would no longer tell the whole story.

What is the difference between the two obesity stages?

  • Clinical obesity is a disease state involving at least one of 18 forms of bodily dysfunction caused by excess fat tissue.
  • Preclinical obesity means a person is at risk of that disease state but does not yet have it and may need interventions to avoid obesity-related dysfunction.

Two people with the same BMI, waist circumference and waist-to-height ratio could receive different classifications depending on whether they had other conditions.

Across the cohorts, 77% to 91% of individuals with preclinical obesity did not progress to clinical obesity within 10 years, depending on the cohort analyzed.

The Lancet Commission says the split could help doctors identify people with the greatest need for treatment. Each organ-dysfunction measure has its own ambiguities. Dr. Aayush Visaria, an internal medicine instructor at Rutgers Robert Wood Johnson Medical School in New Jersey, said more consensus is needed on what actually defines clinical obesity. He did not write the criteria but authored an analysis.

The labels distinguish current organ damage from future risk, though the boundaries remain unsettled.

How many people would change category?

Under the BMI-only framework used in the study, a BMI of 30 or higher means obese. Some people below that threshold would be newly classified as clinically obese if they had obesity-related dysfunction.

A smaller group with BMIs of 30 or higher would no longer meet the clinical definition if they had no relevant dysfunction. For example, an “overweight” BMI plus organ problems could count as clinical obesity, while an “obese” BMI without such problems might not.

Overall, the criteria would produce a small net rise in obesity diagnoses: about 3.3% to 7.4%, depending on the group analyzed.

Dr. Jennifer Hwang, an instructor of medicine at the University of Chicago who published her own analysis, said: “We are definitely missing some people who actually need obesity treatment but just did not meet the BMI criteria.” She noted that the Lancet Commission’s categories could help doctors identify the people with the greatest need for treatment.

Most BMI-defined cases would stay the same, while the net change would come from better detection.

What must happen before clinics adopt it?

More research is needed to show that the Lancet Commission’s criteria improve patient care and are practical in clinical settings. Even the simple body measurements would require training so clinicians could perform them accurately.

The preclinical-clinical split may also complicate treatment decisions. A 2025 analysis noted that some patients who qualify for obesity medications under Food and Drug Administration guidelines could be recharacterized as preclinical and no longer receive a prescription.

Rubino and the commission plan to continue validating the framework, including which forms of organ dysfunction deserve greatest concern and a way to score each patient’s risk.

The new definition looks more informative than BMI alone, but its value depends on accurate measurements, clear clinical rules and further validation.

via livescience.com/feeds/news (Source)

Filed under

  • obesity
  • body-mass-index-bmi
  • body-composition
  • mortality-risk
  • clinical-guidelines
Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Correspondent covering money, funding and market shifts around general science news at SciBeat.

503 articles

Nearby plates

« Previous articleNext article »